Glaxosmithkline Pharmaceuticals valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
39.62×————
18.66×————
10.70×————
49.90×————
Enterprise multiples
10.07×————
29.44×————
30.96×————
Yield
2.5%————
2.0%————
Reference — adjusted share basis
₹2,498.00————
₹63.05₹61.15₹54.75₹34.82₹36.05
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLAXO₹2,498.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersPFIZERABBOTINDIAMEDANTAANTHEMAJANTPHARMIPCALABGLENMARKBIOCONMcap ₹42,319 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————39.62
P/B————18.66
P/Sales————10.70
Price to Free Cash Flow————49.90
Enterprise Multiples
EV/Sales————10.07
EV/EBITDA————29.44
EV/EBIT————30.96
Yield
Earnings Yield %————2.52
FCF Yield %————2.00
Reference — adjusted share basis
Price (FY-end close, adj.)————2,498.00
EPS (adj.)36.0534.8254.7561.1563.05
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.